- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05297890
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
March 26, 2024 updated by: CStone Pharmaceuticals
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hua Hu
- Phone Number: +86 021-60333416
- Email: cstoneRA@cstonepharma.com
Study Locations
-
-
-
Beijing, China
- Beijing Cancer Hospital
-
Beijing, China
- Cancer Hospital Chinese Academy of Medical Sciences
-
Changchun, China
- The First Hospital of Jilin University
-
Changsha, China
- Hunan Cancer Hospital
-
Chengdu, China
- West China Hospital of Sichuan University
-
Chengdu, China
- Sichuan Cancer Hospital & Institute
-
Chongqing, China
- Chinese PLA Army Medical Center
-
Fuzhou, China
- Fujian Cancer Hospital
-
Guangzhou, China
- Sun Yat-sen University Cancer Center
-
Guangzhou, China
- The First Affiliated Hospital, Sun Yat-sen University
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
Hefei, China
- The First Affiliated Hospital of Anhui Medical University
-
Jinan, China
- Shandong Cancer Hospital&Institute
-
Kunming, China
- Yunnan Cancer Hospital
-
Nanchang, China
- The First Affiliated Hospital of Nanchang University
-
Nanchang, China
- The Second Affiliated Hospital of Nanchang University
-
Nanjing, China
- Jiangsu Province Hospital
-
Shanghai, China
- Shanghai Pulmonary Hospital
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shenyang, China
- Liaoning Cancer Hospital and Institute
-
Taiyuan, China
- Shanxi Cancer Hospital
-
Tianjin, China
- Tianjin Medical University Cancer Institute & Hospital
-
Wenzhou, China
- The 1st Affiliated hospital of Wenzhou Medical University
-
Wuhan, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Xi'an, China
- Tangdu Hospital of The fourth Military Medical University Peoples Liberation Army of China
-
Xiamen, China
- Xiamen Humanity Hospital
-
Zhengzhou, China
- Henan provincial people's hospital
-
Zhengzhou, China
- Henan Cancer Hospital
-
Zhengzhou, China
- The First Affiliated Hospital of Zhengzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Provincial People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects with histologically or cytologically confirmed diagnosis of locally advanced or metastatic ROS1 gene arrangement positive NSCLC.
- Subject should have radiological disease progression while on treatment with crizotinib as the only prior ROS1 inhibitor.
- Participants must have been treated with platinum-based doublet chemotherapy for locally advanced/metastatic disease for at least 1 cycle and must have radiological disease progression on or after that. Participants who do not tolerate platinum-based doublet chemotherapy may be included provided they have been treated for at least 1 cycle.
- Prior treatment with small molecules or cytotoxic agents must have completed ≥5 half-lives prior to initiating study treatment; Prior treatment with antibodies must have completed at least 3 weeks prior to initiating study treatment.
- All Subjects must have at least 1 measurable target lesion (intracranial or extracranial) according to RECIST v1.1.
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.
- Age ≥18 years.
- Subjects must have adequate organ function as assessed in the laboratory tests.
- Acute effects of prior anti-cancer treatment resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.
- Serum or urine pregnancy test (for females of childbearing potential) negative at screening.
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.
Exclusion Criteria:
- More than 1 prior chemotherapy regimen prior to enrollment in the locally advanced/metastatic setting.
- Subject's cancer has a known primary driver alteration other than ROS1 gene rearrangement.
- Major surgery within 4 weeks prior to the first dose.
- Radiation therapy within 2 weeks prior to the first dose. Palliative radiation must have been completed at least 48 hours prior to the first dose. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to the first dose. Whole brain irradiation must have completed at least 4 weeks prior to the first dose.
- Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to the first dose.
- Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.
- Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.
- Severe acute or chronic infections.
- Clinically significant cardiovascular disease (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to the first dose).
- Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to the first dose.
- History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
- Evidence of active malignancy within the last 3 years prior to the first dose.
- Concurrent use of any of the prohibited food or drugs required in protocol within 12 days prior to the first dose of administration of lorlatinib.
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, would make the subject inappropriate for entry into this study.
- Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
- Pregnant female subjects; breastfeeding female subjects.
- Any use of traditional Chinese medicines or herbal preparations with anti-tumor indications within 7 days before the first dose of investigational product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lorlatinib
Drug:Lorlatinib 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
|
Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response (DoR) as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
ORR assessed by RECIST version 1.1 per investigator assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
DoR assessed by RECIST version 1.1 per investigator assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Disease control rate (DCR) at 12 and 24 week as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Time to tumor response (TTR) as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Progression-free survival (PFS) as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Intracranial Objective Response (IC-OR) as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Duration of intracranial response (IC-DoR) as assessed by RECIST v1.1 per ICR assessment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Overall survival (OS)
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
To evaluate the safety and tolerability of lorlatinib treatment
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Lorlatinib concentration will be used for population PK analysis
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
patient-reported outcomes (PROs) as assessed by EORTC QLQ-C30 and EORTC QLQ-LC13 (self-assessment questionnaires)
Time Frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 27, 2022
Primary Completion (Actual)
December 26, 2023
Study Completion (Estimated)
November 1, 2025
Study Registration Dates
First Submitted
March 17, 2022
First Submitted That Met QC Criteria
March 17, 2022
First Posted (Actual)
March 28, 2022
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS3011-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
-
TakedaCompletedCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid TumorsSpain, Italy, Netherlands, France
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
PfizerNo longer availableNon Small Cell Lung Cancer ALK Positive or ROS1 PositiveUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK PositiveUnited States
-
Betta Pharmaceuticals Co., Ltd.Active, not recruitingAdvanced or Metastatic Non-small Cell LungChina
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung CancerChina
-
AstraZenecaParexelCompletedEGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerSpain, United States, Italy, Korea, Republic of, Malaysia
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
Clinical Trials on Lorlatinib
-
Guangdong Provincial People's HospitalRecruiting
-
PfizerTerminated
-
Massachusetts General HospitalRecruitingNon-Small Cell Lung Cancer (NSCLC)United States
-
Intergroupe Francophone de Cancerologie ThoraciqueActive, not recruitingNon Small Cell Lung Cancer MetastaticFrance
-
PfizerTerminatedNeuroblastomaAustralia, Korea, Republic of, United States, Portugal, New Zealand, Sweden
-
Nationwide Children's HospitalPfizerNot yet recruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | WHO Grade III Glioma | WHO Grade IV Glioma | Infant Type Hemispheric Glioma | Diffuse Midline Glioma, H3K27-alteredUnited States, Australia, Canada, Germany, Netherlands
-
PfizerCompletedAdvanced Non-Small Cell Lung CancerIndia
-
Guangdong Association of Clinical TrialsNot yet recruitingCarcinoma, Non-Small-Cell Lung | Brain Metastases | Leptomeningeal MetastasisChina
-
Sichuan Cancer Hospital and Research InstituteRecruitingALK-positive Non-small Cell Lung Cancer | Real World StudyChina